Teleflex Incorporated (TFX) – What Are Analysts Thinking About This Stock?

Shares of Teleflex Incorporated (NYSE:TFX) have been given an average recommendation of “Moderate Buy” by the twelve research firms that are covering the company, MarketBeat reports. One equities research analyst has rated the stock with a sell rating, four have given a hold rating, five have assigned a buy rating and two have assigned a strong buy rating to the company. The average 1-year price target among brokerages that have issued a report on the stock in the last year is $155.20.

Several equities research analysts have recently weighed in on the company. Truist Financial increased their price objective on Teleflex from $143.00 to $150.00 and gave the company a “hold” rating in a report on Monday, August 10th. BMO Capital Markets assumed coverage on shares of Teleflex in a report on Wednesday, July 8th. They issued an “outperform” rating and a $159.00 target price on the stock. Wall Street Zen upgraded shares of Teleflex from a “sell” rating to a “hold” rating in a research report on Sunday, August 9th. Piper Sandler reiterated an “overweight” rating and issued a $169.00 price target (up from $160.00) on shares of Teleflex in a research report on Friday, August 7th. Finally, Mizuho increased their price target on shares of Teleflex from $140.00 to $145.00 and gave the stock a “neutral” rating in a research note on Wednesday, July 15th.

Teleflex Stock Up 0.7%

TFX opened at $125.01 on Tuesday. The business’s 50-day simple moving average is $132.35 and its 200-day simple moving average is $129.68. The company has a debt-to-equity ratio of 0.94, a quick ratio of 2.12 and a current ratio of 2.60. Teleflex has a one year low of $100.18 and a one year high of $145.00. The stock has a market capitalization of $5.30 billion, a P/E ratio of -5.37, a price-to-earnings-growth ratio of 0.84 and a beta of 0.83.

Teleflex (NYSE:TFX) last announced its earnings results on Thursday, August 6th. The medical technology company reported $1.76 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.28 by $0.48. The firm had revenue of $570.33 million during the quarter, compared to analysts’ expectations of $559.59 million. Teleflex had a positive return on equity of 11.93% and a negative net margin of 39.67%. The business’s revenue was up 28.9% on a year-over-year basis. During the same period in the prior year, the firm earned $3.73 EPS. Teleflex has set its FY 2026 guidance at 6.900-7.200 EPS. Analysts anticipate that Teleflex will post 7.22 EPS for the current year.

Teleflex Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Wednesday, September 30th. Stockholders of record on Friday, August 14th were issued a $0.34 dividend. This represents a $1.36 dividend on an annualized basis and a dividend yield of 1.1%. The ex-dividend date of this dividend was Friday, August 14th. Teleflex’s dividend payout ratio is presently -5.84%.

Institutional Investors Weigh In On Teleflex

Several hedge funds have recently made changes to their positions in the business. BlackRock Inc. acquired a new stake in Teleflex during the 2nd quarter worth approximately $688,537,000. Jupiter Topco LLC acquired a new stake in shares of Teleflex during the second quarter worth $550,456,000. Irenic Capital Management LP acquired a new stake in shares of Teleflex during the first quarter worth $104,061,000. Pzena Investment Management LLC acquired a new stake in shares of Teleflex during the second quarter worth $76,462,000. Finally, Bank of America Corp DE purchased a new position in Teleflex in the 2nd quarter valued at $61,156,000. Institutional investors and hedge funds own 95.62% of the company’s stock.

Teleflex Company Profile

Teleflex Incorporated is a global medical technology company that develops, manufactures and supplies specialty medical devices for hospitals, physicians and other healthcare providers. Its products are designed to support minimally invasive procedures, critical care and a range of clinical applications.

The company’s portfolio includes devices for vascular access and intervention, anesthesia, respiratory care, emergency medicine, surgery, urology and pain management. Teleflex markets products under brands including Arrow, which is known for vascular access and catheter-based technologies, as well as other specialized product lines used in hospitals and outpatient settings.

Teleflex serves healthcare markets in North America, Europe, Asia and other international regions.